Equities

Phibro Animal Health Corp

Phibro Animal Health Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)23.99
  • Today's Change0.23 / 0.97%
  • Shares traded60.27k
  • 1 Year change+132.46%
  • Beta0.5117
Data delayed at least 15 minutes, as of Nov 22 2024 19:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Phibro Animal Health Corp had net income fall -92.59% from 32.61m to 2.42m despite revenues that grew 4.07% from 977.89m to 1.02bn over the same period.
Gross margin31.47%
Net profit margin1.66%
Operating margin6.85%
Return on assets1.80%
Return on equity6.55%
Return on investment2.20%
More ▼

Cash flow in USDView more

In 2024, Phibro Animal Health Corp increased its cash reserves by 71.05%, or 29.33m. The company earned 87.59m from its operations for a Cash Flow Margin of 8.61%. In addition the company used 48.19m on investing activities and also paid 6.77m in financing cash flows.
Cash flow per share1.32
Price/Cash flow per share17.92
Book value per share6.38
Tangible book value per share3.98
More ▼

Balance sheet in USDView more

Phibro Animal Health Corp has a Debt to Total Capital ratio of 64.72%, a lower figure than the previous year's 167.99%.
Current ratio3.23
Quick ratio1.69
Total debt/total equity1.83
Total debt/total capital0.6472
More ▼

Growth rates in USD

Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items fell by -92.59%. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked below the industry average relative to its peers.
Div yield(5 year avg)2.29%
Div growth rate (5 year)0.85%
Payout ratio (TTM)111.70%
EPS growth(5 years)-46.35
EPS (TTM) vs
TTM 1 year ago
-16.14
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.